Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Grail

Simple blood test can pick up cancer cases in ‘false positive’ patients – study

The Galleri blood test by Grail can be given annually and looks for the DNA ‘fingerprint’ of more than 50 deadly cancers.

Evening Standard

New blood test can detect more than 50 cancers early

Galleri has been dubbed the holy grail of cancer tests

The Independent UK

‘Holy grail’ blood test for more than 50 cancers delivers ‘exciting’ results

The Galleri test identifies DNA in the bloodstream that has been shed by cancer cells, giving the earliest signs somebody may have the disease.

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Top Tech Disruptors to Watch

Big change catalyzed by top tech disruptors often leads to big growth.

Kiplinger

13 Surprising Companies Jeff Bezos Bet On

Bezos' venture capital firm has invested in biotech companies seeking to cure cancer, educational tech companies and more. Here's a look at some of his investments.

GOBankingRates

Why Cathie Wood Is Loading Up on This Hot Growth Stock (And Should You?)

This dip in Illumina’s stock could be an attractive opportunity for long-term growth investors.

Barchart

3 Medical Technology Stocks Outperforming in 2025

Three med-tech stocks, TransMedics, Insulet, and GRAIL, are outperforming the market and their sector while forming bullish technical patterns.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Canyon launches DT Swiss developed suspension fork with 40mm of travel

The new suspension fork, aimed at gravel riding is the culmination of a 4-year project with DT Swiss

Cycling Weekly

Canyon launches new suspension fork and Grail RIFT gravel bike: One is promising but the other feels a little mismatched

The brand's new suspension fork has been designed in partnership with DT Swiss and will feature on a Grail gravel bike

Cycling News

5 Momentum Stocks to Buy Now

Amid volatile trade and rising uncertainty, these momentum stocks have shown strong signs of leadership in the first half of 2025.

Kiplinger

3 Under-the-Radar Stocks that Legendary Investor Bill Miller Thinks Are Cheap

He believes these stocks are trading at compelling valuations and could outperform the broader market.

Barchart

Canyon Grail CF SLX 8 AXS review: A gravel race bike that can do it all

The Canyon Grail CF SLX is a rapid gravel race bike that can do everything well

Cycling News

GRAIL: Biotech Stock Targeting $100B Cancer Market

GRAIL is a small biotech stock on the rise big time recently. Its innovative technology gives it the opportunity to capitalize on a massive addressable market.

MarketBeat

Canyon Grail CF SL 7 AXS review: a gravel bike of two halves?

The integrated cockpit and aero tubing are somewhat at odds with the Grail's taller stack height

Cycling Weekly

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Biotech Stocks With Anticipated Strong Earnings Reports

With highly effective drugs and treatment options, chronic disease prevalence, and adoption of technology, the biotech market is thriving. Hence, fundamentally solid biotech stocks Illumina (ILMN), Amgen (AMGN), and Entrada Therapeutics (TRDA) could be ideal with anticipated strong earnings reports. Read more.

Bike Perfect

The Canyon Grail CF SLX 8 AXS is one of the best gravel bikes I have ever tested but I would never buy one

Canyon’s Grail is an optimized gravel racing machine, but is it the pinnacle of gravel tech or death by integration?

Barchart

What You Need to Know Ahead of Illumina's Earnings Release

Illumina is expected to release its second-quarter earnings next month, analysts expect a double-digit earnings dip.

StockNews.com

3 Biopharma Stocks to Buy for Long-Term Growth

With the rising investment in personalized medicine research and development and growing clinical trials, the biopharma industry’s prospects appear promising. Hence, quality biotech stocks, Alnylam Pharmaceuticals (ALNY), Illumina (ILMN), and Gilead Sciences (GILD) with long-term growth might be solid buys. Read more….

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Biotech Stocks to Monitor for May Moves

The biotech industry is well poised to flourish, buoyed by its strong emphasis on technology-driven advancements to address complex medical challenges and government funding. Hence, quality biotech stocks Harmony Biosciences Holdings (HRMY), Illumina (ILMN), and Compugen (CGEN) could be ideal watchlist additions for May. Read more….

Golf Monthly

'You Know You’ve Still Got To Go Through Hell To Get There, But If You Can Get It At Stage 2 or 3'... Hall Of Famer Juli Inkster On New Cancer Screening

Are we entering a new worldwide era for cancer screening?

Top News

Illumina Sheds Light, Divests its Cancer Tester, Grail

Illumina, a beacon in genetic science, is set to unfurl its stake in Grail-the stellar creator of cancer-detecting tests–in a dance of corporate divestiture.

StockNews.com

3 Healthcare Stocks to Buy With Major Value Behind Them

The healthcare industry is set for growth due to the growing demand for quality healthcare services and the integration of advanced technologies in offerings and operations. Therefore, it could be wise to buy fundamentally strong medical stocks HCA Healthcare (HCA), LifeVantage (LFVN), and Semler Scientific (SMLR). Read more….

The Independent UK

EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail

The European Union is ordering U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators

Fortune

Inside Illumina’s bruising proxy battle with billionaire activist investor Carl Icahn

Illumina’s contentious acquisition of cancer test maker Grail brought billionaire Carl Icahn to the company’s doorstep.

The Independent UK

EU fines US firm Illumina $475 million for jumping gun on buying cancer-screening company Grail

The European Union has slapped a $475 million fine on U.S. biotech giant Illumina for buying out cancer-screening company Grail without the approval of the 27-nation bloc’s antitrust watchdog

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.